CancerVax unit says preclinical data on D93 antibody inhibits breast, pancreatic tumors

By Lisa Kerner

Erie, Pa., April 4 - CancerVax Corp. said its wholly owned subsidiary, Cell-Matrix, Inc., presented preclinical data indicating that D93, the company's leading anti-angiogenic and anti-tumorigenic, humanized, monoclonal antibody, inhibited human breast and pancreatic tumor growth in animal models.

The presentation was made at the 97th Annual Meeting of the American Association for Cancer Research in Washington, D.C., according to a news release.

In a poster entitled "Anti-Denatured Collagen Antibody D93: An Extra-Cellular Matrix Approach to Treatment of Solid Tumors and Metastasis," CancerVax scientists highlighted results obtained in an orthotopic, staged human breast tumor model using human MDA-MB-435 cells implanted in mice.

In this model, D93 was shown to inhibit tumor growth in a dose-dependent manner, with the maximum inhibition obtained at a dose of 10 mg/kg per week and was compared to D93 administered in combination with Taxol (paclitaxel).

The combination of D93 plus Taxol inhibited tumor volume by 66% versus a control antibody; the results for Taxol and D93 as single agents were 49% and 39%, respectively, versus the control antibody.

"The ability of the D93 antibody to target unique sites on collagen that are exposed in tumor tissues and that may be important in the growth and vascularization of tumors represents a novel therapeutic approach," president and chief executive officer David F. Hale said in the release.

"The results presented at AACR support earlier findings indicating that D93 may have the potential to treat a variety of solid tumors."

Located in Carlsbad, Calif., CancerVax is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.